EA201991471A1 - WAYS OF INTRODUCTION OF HEPSIDINE - Google Patents

WAYS OF INTRODUCTION OF HEPSIDINE

Info

Publication number
EA201991471A1
EA201991471A1 EA201991471A EA201991471A EA201991471A1 EA 201991471 A1 EA201991471 A1 EA 201991471A1 EA 201991471 A EA201991471 A EA 201991471A EA 201991471 A EA201991471 A EA 201991471A EA 201991471 A1 EA201991471 A1 EA 201991471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepsidine
introduction
ways
hepcidin
decrease
Prior art date
Application number
EA201991471A
Other languages
Russian (ru)
Inventor
Лакхмир Чавла
Джордж Тидмарш
Original Assignee
Ла Хойя Фармасьютикал Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ла Хойя Фармасьютикал Компани filed Critical Ла Хойя Фармасьютикал Компани
Priority claimed from PCT/US2017/067400 external-priority patent/WO2018118979A1/en
Publication of EA201991471A1 publication Critical patent/EA201991471A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к применению гепсидина в терапевтических способах для лечения различных состояний, при которых снижение концентрации сывороточного железа может быть полезным.The present invention relates to the use of hepcidin in therapeutic methods for treating various conditions in which a decrease in serum iron concentration may be beneficial.

EA201991471A 2017-06-30 2017-12-19 WAYS OF INTRODUCTION OF HEPSIDINE EA201991471A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527354P 2017-06-30 2017-06-30
PCT/US2017/067400 WO2018118979A1 (en) 2016-12-19 2017-12-19 Methods of administering hepcidin

Publications (1)

Publication Number Publication Date
EA201991471A1 true EA201991471A1 (en) 2020-01-28

Family

ID=69374483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991471A EA201991471A1 (en) 2017-06-30 2017-12-19 WAYS OF INTRODUCTION OF HEPSIDINE

Country Status (1)

Country Link
EA (1) EA201991471A1 (en)

Similar Documents

Publication Publication Date Title
CL2015003731A1 (en) Bromodomain Inhibitors
PH12016500358A1 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EA201891910A1 (en) PAD4 HETEROARYLINARY INHIBITORS
EA201891366A1 (en) HUMANIZED ANTIBODIES AGAINST CD73
EA202091540A1 (en) ANTIBODIES TO LILRB2
EA201990293A1 (en) MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
EA201890131A1 (en) IMMUNOMODULATION AND TREATMENT OF SOLID TUMORS BY ANTIBODIES THAT SPECIFICALLY CONNECT CD38
MX2018010295A (en) Antibodies having specificity for btla and uses thereof.
PH12018501443A1 (en) Methods of administering hepcidin
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201891251A1 (en) PAD4 BICYCLIC INHIBITORS
EA201890185A1 (en) METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID
EA201792227A1 (en) TREATMENT OF LUNG CANCER WITH GLUTAMINASE INHIBITORS
MX2015011772A (en) Anti-hepcidin antibodies and uses thereof.
EA201891347A1 (en) Aza-benzimidazole inhibitors PAD4
EA201890747A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
MX2017000306A (en) Methods for treating hypotension.
MX2020003219A (en) Antibodies having specificity for btn2 and uses thereof.
MX2020010269A (en) Methods of treating ulcerative colitis.
ECSP18002725A (en) AGENTS, USES AND METHODS FOR TREATMENT
EA201891527A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF CANCER ETHESIS
EA201891528A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF GASTRIC CANCER
MX2019003755A (en) Dosing regimen of avelumab for the treatment of cancer.